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Abstract. Spleen metastasis is extremely rare in patients with 
lung cancer. However, recent improvements in imaging modali-
ties may enable the antemortem diagnosis of spleen metastasis. 
The present study reports the case of a female patient with 
lung adenocarcinoma and spleen metastasis. The patient devel-
oped isolated spleen metastasis in the postoperative course. 
This rare metastasis was detected in a follow-up abdominal 
computed tomography (CT) scan without any symptoms, 
and was confirmed by fluorodeoxyglucose positron emission 
tomography (FDG-PET)/CT scan. Although very rare, chest 
physicians and thoracic surgeons should be alert to the possi-
bility of spleen metastasis development when evaluating the 
follow-up abdominal CT scan. FDG-PET/CT scanning and 
an interventional approach should be considered to clarify the 
possibility of spleen metastasis.
Introduction
In patients with hematological malignancies, the spleen is a 
common site of involvement (1,2). The incidence of metastasis 
to the spleen in patients with lung cancer has been reported to 
be a few percent to 21% when investigated by autopsy (3,4). 
By contrast, however, reports of spleen metastasis from lung 
cancer either at the time of initial diagnosis or during the clin-
ical course are extremely rare (5). In the present study, the case 
of a patient with lung adenocarcinoma who developed isolated 
metastasis to the spleen following surgery is described. A 
review of this rare metastasis in patients with lung cancer was 
also conducted.
Case report
A 63-year-old woman presented with the incidental detection 
of a nodule 30 mm in diameter in the left lung on chest radiog-
raphy, at the Mito Medical Center of the University of Tsukuba 
(Mito, Japan). At the age of 57 years, the patient had undergone 
a left mastectomy due to breast cancer; however the patient 
was asymptomatic and had been in good health since then. The 
physical examination was unremarkable. The chest computed 
tomography (CT) scan revealed a well-circumscribed mass in 
the left lower lobe of the lung that measured 30x27x18 mm with 
specular appearance (Fig. 1). The routine laboratory tests were 
normal, as were tumor markers including carcinoembryonic 
antigen. The patient was diagnosed with adenocarcinoma on 
the basis of pathological examination of transbrochial biopsy 
specimens. Distant metastasis was not detected. Informed 
consent was obtained, and the patient underwent lobectomy 
of the left lower lung and mediastinal lymph node dissection. 
The final pathological diagnosis was lung adenocarcinoma 
staged as pT3N2M0, stage IIIB. An EGFR exon 19 deletion 
was identified. Soon after the surgical resection, the patient 
received adjuvant postoperative chemotherapy. However, 
12 months after the surgery, a follow-up abdominal CT scan 
revealed three nodular lesions of ≤10 mm in diameter in the 
spleen (Fig. 2). No metastatic lesions in the liver, adrenal gland 
and abdominal lymph nodes were found. The splenic nodular 
lesions were considered to indicate an inflammatory disease 
such as granuloma. However, fluorodeoxyglucose positron 
emission tomography (FDG-PET)/CT confirmed uptake in 
these nodules in the spleen, but there was no other metastatic 
sites (Fig. 3). The patient then underwent splenectomy. As the 
resected tumor had the same characteristics as the specimen 
of the primary lung carcinoma and was positively immunos-
tained for thyroid transcription factor-1 and cytokeratin 7, the 
tumor was pathologically diagnosed as spleen metastasis from 
lung adenocarcinoma (Fig. 4). Thereafter, the patient received 
treatment with four courses of cisplatin and vinorelbine, and 
was well without any signs of tumor progression.
Discussion
Although numerous cases of abdominal visceral metastases 
from lung cancer have been reported (6,7), metastasis to the 
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Figure 3. Fluorodeoxyglucose-positron emission tomography/computed tomography confirmed uptake in the nodules in the spleen. There were no other sites 
of metastasis.
Figure 2. Follow‑up abdominal computed tomography scan revealed metastatic lesions of diameter ≤15 mm in the spleen (arrows).
Figure 1. Chest computed tomography revealed a well-circumscribed mass in the lower lobe that measured 34x30x24 mm and had a specular appearance.
Figure 4. (A) Primary resected lung adenocarcinoma lesion and (B) resected spleen tumor (hematoxylin and eosin staining, x200). (C) Immunostaining of 
thyroid transcription factor-1 in the resected spleen tumor (hematoxylin and eosin staining, x200).
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spleen from lung cancer is considered to be rare and is usually 
detected only at autopsy (8,9). The early detection of metastasis 
to the spleen is challenging since the majority of patients are 
asymptomatic in the early stage of such metastasis. However, 
as the availability of CT scanning and ultrasonography has 
increased, this has enabled spleen metastasis to be diagnosed 
more accurately (10-12). CT scanning and ultrasonograpy can 
provide a quick, direct and non-invasive evaluation of spleen 
metastasis; however, some metastasis cannot be identified by 
ultrasonograpy because of the effect of air in the stomach and 
colon. Therefore, abdominal CT scans should be considered 
for use if spleen metastasis is suspected. Several studies have 
reported the clinical significance of FDG-PET/CT scanning in 
the detection of spleen metastasis from lung cancer (13-17). In 
the present case, FDG-PET/CT was useful for confirming the 
presence of malignant lesions in the spleen.
We previously evaluated spleen metastasis from lung 
cancer (18). In the study, 12 (1.2%) of 997 consecutive patients 
with lung cancer had spleen metastasis, and isolated spleen 
metastasis in the absence of widespread disease was considered 
an extremely rare event (18). All 12 cases had accompanying 
metastasis to other organs, including the paraaortic lymph 
nodes, bone, lung and liver, which also suggested a poor 
outcome for patients with spleen metastasis (18). Moreover, 
it is noteworthy that all 12 patients exhibited more than one 
metastatic site in the abdomen. The most common site of 
metastasis was the lymph nodes in the abdomen. Therefore, 
it was concluded at that time that spleen mass accompanying 
metastasis to other abdominal organs in patients with a known 
lung cancer should be regarded as a metastasis. We recently 
conducted a review of patients with lung cancer and spleen 
metastasis, and found 20 such patients (10-15,17,19-30). In these 
20 patients, it was notable that all but 4 of the 20 patients had no 
abdominal metastasis other than spleen metastasis. Therefore, 
it should now be recognized that spleen metastasis is not 
necessarily accompanied by abdominal organ metastasis. The 
difference between our previous study (18) and the recent case 
reports might be due to the development of imaging modalities 
and the advancement of knowledge in such rare metastasis.
The incidence of spleen metastasis is considered to differ 
among histologic types of lung cancer (3,4,18). Small cell 
lung cancer has been recognized to be the most common cell 
type likely to metastasize to the spleen and squamous cell 
lung carcinoma the least likely (3,4). In our previous study of 
lung cancer metastasis, adenocarcinoma had almost the same 
frequency of spleen metastasis as small cell lung cancer (1.3 
vs. 2.0%, respectively), while in squamous cell carcinoma, 
only 0.6% of patients developed spleen metastasis (18). When 
reviewing recent case reports, however, 5 of the 20 patients 
with lung cancer and spleen metastasis had squamous cell 
carcinoma (12,21,27-29). These results indicate that the spleen 
is a possible site to which disease may spread in patients with 
advanced or recurrent lung cancer, including those with squa-
mous cell carcinoma of the lung.
With regard to the radiological classification of spleen 
metastasis dependent on pathological examination, there may 
be four types, known as solitary, multiple, microscopic and 
diffuse. Sardenberg et al presented three main macroscopic 
patterns: Macronodular, micronodular and diffuse (17). The 
latter two types might not be apparent in abdominal CT scans, 
although FDG-PET/CT scanning may detect the diffuse type 
of spleen metastasis. In our previous study, the solitary nodular 
type was the most common, and in a review of recent case 
reports, the solitary type was confirmed as the most common 
type (10,12-17,19-21,23,26). The differential diagnosis of a soli-
tary nodule or nodules in the spleen includes several diseases, 
either benign or malignant (31). In differential diagnosis, 
FDG-PET/CT scanning can be useful to identify whether the 
lesion is malignant (13-17).
A mass in the spleen accompanied by metastasis to other 
abdominal organs in a patient known to have lung cancer or 
with a history of lung cancer should be regarded as a metas-
tasis. In addition, an isolated splenic mass in the absence of 
abdominal metastatic disease elsewhere should also be consid-
ered likely to represent a metastasis. An isolated spleen mass 
identified at the initial diagnosis or during the clinical course 
in a patient with lung cancer should be considered for an inter-
ventional approach and can provide pathological material.
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